The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XSNX | -66.67% | -99.98% | -81.41% | -100% |
| S&P | +14.43% | +77.25% | +12.13% | +581% |
NovAccess Global, Inc. is a biopharmaceutical company, which engages in the provision of diagnostics, therapeutics in cancer, and neurological diseases and the development of immunotherapies to treat brain tumor patients. The company was founded on February 25, 1997 and is headquartered in Cuyahoga County, OH.
No news articles found for NovAccess Global.
| Q3 2024 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $510.30K | 0.0% |
| Market Cap / Employee | $255.15K | 0.0% |
| Employees | 2 | 0.0% |
| Net Income | -$2,532.56K | 0.0% |
| EBITDA | -$96.22K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2024 | YOY Change | |
|---|---|---|
| Net Cash | $20.89K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $2.22M | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -4270.66% | 0.0% |
| Return On Invested Capital | 57.94% | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$55.43K | 0.0% |
| Operating Free Cash Flow | -$55.43K | 0.0% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change |
|---|---|---|---|---|
| Price to Book | -0.02 | -0.02 | -0.02 | - |
| Price to Tangible Book Value | -0.02 | -0.02 | -0.02 | - |
| Enterprise Value to EBITDA | -30.90 | -23.10 | -77.47 | - |
| Total Debt | $2.16M | $2.09M | $2.22M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
